Vaxart, Inc.
For the period ended May 19, 2026. Filed May 19, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
May 19, 2026 · Filed May 19, 2026
Use the contents to explore the available documents and sections.
Contents
EX-99.1 · Vaxart Files Preliminary Proxy Statement and Issues Open Letter to Shareholders
Vaxart Files Preliminary Proxy Statement and Issues Open Letter to Shareholders
Company is Entering a Pivotal Phase to Demonstrate Value of its Unique Oral Vaccine Platform
Emphasizes Need for the Right Board Leadership at Critical Strategic Juncture
Encourages Shareholders to Visit Vote.Vaxart.com for Additional Information
SOUTH SAN FRANCISCO, Calif., May 19, 2026 -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform, today announced that it has filed preliminary proxy materials with the Securities and Exchange Commission in connection with its upcoming Annual Meeting of Stockholders scheduled to be held on July 16, 2026.
In conjunction with the preliminary proxy filing, Vaxart issued an open letter to shareholders highlighting the Board’s urgent focus on realizing the market potential of the Company’s unique oral vaccine platform and creating value for all shareholders. The full text of the letter is as follows:
Dear Fellow Vaxart Shareholders:
Vaxart is entering a pivotal phase as we demonstrate the value of our unique oral vaccine platform and capitalize on our innovative scientific advancements. Ahead of our upcoming 2026 Annual Meeting of Stockholders, we will be seeking your vote to support our Board of Directors, enabling Vaxart to continue the important work underway. Over the last year, we have:
| ● | Made meaningful progress advancing our clinical roadmap; |
| ● | Strengthened our near-term financial position to provide the runway to capture the potential upside from key upcoming milestones; and |
| ● | Refreshed and enhanced our Board with the addition of Dr. James Breitmeyer, M.D., Ph.D., who brings more than 35 years of extensive clinical development, vaccine and regulatory experience. |
While we are making significant progress, we understand there is more work to do. We are moving with urgency, and we are focused on proving that oral delivery is the future of vaccination. We are committed to disciplined execution to realize the market potential of our platform and the opportunities we believe lie ahead for our shareholders.
By contrast, a small group of dissident shareholders is seeking to disrupt our progress. In connection with our upcoming Annual Meeting, they have nominated three candidates to replace highly qualified and engaged directors on our Board. Your support will be critical to ensure we remain positioned for success and able to realize the value of your investment in Vaxart.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.